Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
NCT ID: NCT06897644
Last Updated: 2025-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
340 participants
INTERVENTIONAL
2025-03-27
2030-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas
NCT03779464
A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy
NCT03331640
Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma
NCT02172976
Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients
NCT03278015
Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection
NCT02506842
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The induction chemotherapy regimen will be mFOLFIRINOX as per standard of care. Treatment must be continued for up to a maximum of 14 weeks, corresponding to \~ 6 bi-weekly cycles. A minimum of 4 treatment cycles administered is necessary for the patient to be evaluable for randomization.
Radiological tumor assessment will be performed before the start and after completion of induction chemotherapy. Patients with complete/partial response or stable disease (CR/PR/SD) or without evidence of progressive disease (PD) in case of non-measurable disease will be randomized in a 1:1 ratio.
Stratification factors will be ECOG Performance status (PS, 0 vs 1) and disease extension (LAD vs metastatic with presence of liver metastases vs metastatic without presence of liver metastases).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ARM A - continuation of mFOLFIRINOX
Patients in Arm A will receive continuation of the same regimen used as induction chemotherapy:
* Oxaliplatin 85 mg/sqm;
* Irinotecan 150 mg/sqm;
* Leucovorin 400 mg/sqm (racemic) or l-Leucovorin 200 mg/sqm;
* 5-FU 2400 mg/sqm 46-hours infusion; every 2 weeks. Treatment will continue until PD, unacceptable toxicity, informed consent withdrawal, or patient's death.
In case of permanent discontinuation of one or more compounds due to unacceptable toxicity, treatment with the other agent(s) may be continued until PD.
Oxaliplatin
85 mg/sqm iv over 2 hours day 1
Irinotecan (CPT-11)
150 mg/sqm iv over 60 minutes day 1
Leucovorin
Leucovorin 400 mg/sqm (racemic) or l-Leucovorin 200 mg/sqm over 2 hours day 1
5-FU (5-fluorouracil)
2400 mg/sqm 46-hours infusion
ARM B - switch maintenance with Gem-NabP
Patients in Arm B will receive:
* Gemcitabine 1000 mg/sqm on Days 1,8,15 of every 28-day cycles;
* Nab-Paclitaxel 125 mg/sqm on Days 1,8,15 of every 28-day cycles. Treatment will continue until PD, unacceptable toxicity, informed consent withdrawal, or patient's death.
In case of permanent discontinuation of one compound due to unacceptable toxicity, treatment with the other agent may be continued until PD in each arm.
gemcitabine
1000 mg/sqm over 30 minutes on Days 1,8,15 of a 28-day cycles
Nab-paclitaxel
125 mg/sqm over 30 minutes on Days 1,8,15 of a 28-day cycles
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxaliplatin
85 mg/sqm iv over 2 hours day 1
Irinotecan (CPT-11)
150 mg/sqm iv over 60 minutes day 1
Leucovorin
Leucovorin 400 mg/sqm (racemic) or l-Leucovorin 200 mg/sqm over 2 hours day 1
5-FU (5-fluorouracil)
2400 mg/sqm 46-hours infusion
gemcitabine
1000 mg/sqm over 30 minutes on Days 1,8,15 of a 28-day cycles
Nab-paclitaxel
125 mg/sqm over 30 minutes on Days 1,8,15 of a 28-day cycles
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must be ≥18 years.
* Histologically or cytologically confirmed unresectable locally advanced or metastatic pancreatic adenocarcinoma eligible for treatment in the first-line setting.
* Presence of measurable or non-measurable disease assessed by CT scan and/or MRI according to RECIST 1.1. Note: any lesion which has been subjected to percutaneous therapies or radiotherapy should not be considered measurable, unless the lesion has clearly progressed since the procedure.
* Availability of archival tumor sample (primary tumor or metastatic site) for biomarker analysis.
* ECOG performance status of 0-1 (if age \< 70 years). If age ≥70 years, ECOG PS must be 0.
* Estimated life expectancy \> 3 months.
* Adequate baseline hematologic function characterized by the following at screening:
* Absolute Neutrophil Count (ANC) ≥ 1.5 × 109/L.
* Platelets count ≥ 100 × 109/L.
* Hemoglobin ≥ 9 g/dl. Note: prior transfusions for patients with low hemoglobin are allowed.
* Adequate liver function characterized by the following at screening:
* Serum total bilirubin ≤ 1.5 × ULN and \< 2 mg/dL. Note: Subjects with Serum total bilirubin ≥ 1.5 × ULN and conjugated bilirubin ≤ ULN or \< 40% of total bilirubin are allowed.
* Serum transaminases (AST and/or ALT) \< 3 x ULN (\< 5 x ULN in presence of liver metastasis). In participants with elevated AST or ALT, the values must be stable for at least 2 week and with no evidence of biliary obstruction by imaging.
* Adequate renal function, i.e. serum creatinine ≤ 1.5 x institutional ULN and calculated by Cockroft-Gault formula or directly measured creatinine clearance ≥ 50 mL/min.
* Adequate coagulation functions as defined by International Normalized Ratio (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless receiving anticoagulation therapy).
* No presence of complete dihydropyrimidine dehydrogenase (DPYD) enzyme deficiency (homozygous of the following DPYD polymorphisms: c1679GG, c1905+1AA, c2846TT) with DPYD gene testing mandatory at screening as per national guidelines. UDP-glucuronosyltransferase 1A1 (UGT1A1) testing is not mandatory. However, if UGT test is routinely performed in the participating centers, enrolment of patients carriers of variants of DPYD and homozygous variant UGT1A1 \[7/7\] has to be discussed with the Sponsor.
* Women of childbearing potential must agree to remain abstinent (refrain from sexual intercourse) or use highly effective contraceptive methods, as defined in APPENDIX V of the full protocol, during the treatment period and for at least 7 months after the last administration of study treatments.
* Negative serum pregnancy test within 7 days of starting study treatment in pre-menopausal women and women \<1 year after the onset of menopause.
* Men must agree to remain abstinent (refrain from sexual intercourse) or use highly effective contraceptive methods during the treatment period and for at least 7 months after the last administration of study treatments.
* Participants must agree not to donate eggs/sperm for future use for the purposes of assisted reproduction during the study and for a period of 7 months after receiving the last dose of study treatment. Female and male participants should consider preservation of eggs/sperm prior to study treatment as anti-cancer treatments may impair fertility.
Exclusion Criteria
* Previous or concurrent systemic (e.g. cytotoxic or targeted or other experimental drugs) therapy for advanced pancreatic adenocarcinoma.
Note: previous (neo)adjuvant or perioperative anti-cancer therapy for non-metastatic, resectable or borderline resectable PDAC, associated with surgery on the primary tumor, is allowed if \> 9 months have elapsed from the last dose of therapy and documented disease progression or relapse.
* Major surgery or radiation therapy performed within \<4 weeks before randomization. Palliative radiotherapy to bone lesions is allowed if performed \> 2 weeks prior to start of study treatment. Patients must have recovered from an effect from major surgery.
* Known allergy or hypersensitivity to study drugs and/or their excipients.
* Unresolved toxicity ≥ CTCAE grade 2 attributed to any prior therapies (e.g. grade ≥2 peripheral neurotoxicity), excluding anemia or alopecia.
* Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that requires directed therapy (such as radiotherapy or surgery) or increasing doses of corticosteroids 2 weeks prior to study entry. Participants with treated symptomatic brain metastases should be neurologically stable for 4 weeks post-treatment and prior to study entry.
* Any known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years prior to study entry except for curatively treated basal cell carcinoma of the skin, in situ carcinoma of the cervix, and prostate cancer.
* Know active uncontrolled hepatitis B or hepatitis C. Patients with a past or resolved HBV infection are eligible. Patients with chronic disease controlled by antiviral therapy or requiring prophylactic treatment are eligible.
* Chronic or current active infectious disease requiring systemic antibiotics or antifungal treatment within 2 weeks prior to enrollment.
* Known uncontrolled HIV infection. HIV-positive patients are eligible if their CD4+ cell count amounts to 300 cells per μL or more; HIV viral load must be undetectable per standard of care assay, and patients must be compliant with antiretroviral treatment.
* Pregnant or breast-feeding patient, or patient planning to become pregnant within 7 months after the end of treatment.
* Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA \> II, unstable angina pectoris, history of myocardial infarction within 3 months before study entry, significant arrhythmia).
* Presence of psychiatric disorder precluding understanding of information of trial related topics and giving informed consent.
* Any serious underlying medical conditions (judged by the investigator), that could impair the ability of the patient to participate in the trial.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rising Tide Foundation
OTHER
Gruppo Oncologico del Nord-Ovest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Monica Niger, MD
Role: PRINCIPAL_INVESTIGATOR
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro Di Riferimento Oncologico Di Aviano
Aviano, Italy, Italy
University Hospital Consorziale Policlinico
Bari, Italy, Italy
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Brescia, Italy, Italy
ASST Ospedale Maggiore di Crema
Crema, Italy, Italy
Azienda Socio Sanitaria Territoriale Di Cremona
Cremona, Italy, Italy
Careggi University Hospital
Florence, Italy, Italy
IRCCS Ospedale Policlinico San Martino
Genoa, Italy, Italy
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Meldola, Italy, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Milan, Italy, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy, Italy
Istituto Europeo Di Oncologia S.r.l.
Milan, Italy, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy, Italy
Humanitas Istituto Clinico Catanese S.p.A.
Misterbianco, Italy, Italy
Azienda Sanitaria Locale Napoli 1 Centro
Napoli, Italy, Italy
Azienda Ospedaliero-Universitaria Maggiore Della Carità
Novara, Italy, Italy
Istituto Oncologico Veneto
Padua, Italy, Italy
Azienda Ospedaliero Universitaria Parma
Parma, Italy, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy, Italy
Azienda Sanitaria Territoriale Di Pesaro E Urbino
Pesaro, Italy, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy, Italy
Azienda Sanitaria Locale Della Provincia Di Biella
Ponderano, Italy, Italy
Azienda USL Toscana Centro
Prato, Italy, Italy
Azienda Unita Sanitaria Locale Della Romagna
Ravenna, Italy, Italy
I.F.O. Istituti Fisioterapici Ospitalieri
Rome, Italy, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy, Italy
Humanitas Mirasole S.p.A.
Rozzano, Italy, Italy
Pia Fondazione Di Culto E Religione Cardinale Giovanni Panico
Tricase, Italy, Italy
Azienda Sanitaria Universitaria Friuli Centrale
Udine, Italy, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-515214-41-00
Identifier Type: CTIS
Identifier Source: secondary_id
PANThEON
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.